Evolent Health, Inc. reported results for the quarter ended 2026 with revenue rising to $652.52M from $444.33M a year earlier while the company narrowed its loss; diluted loss per share improved to ($0.25) from ($0.44).
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$652.52M$444.33M46.9% | Net income²($28.36M)($51.09M)44.5% | Diluted EPS³($0.25)($0.44)43.2% |
¹ Reported as “Revenue (1)”. ² Reported as “Net loss attributable to common shareholders of Evolent Health, Inc.”. ³ Reported as “Diluted loss per common share”.
Business Highlights
- Revenue growth was driven by new Performance Suite contract go-lives and expansion in oncology services, contributing to higher platform scale and PMPM fees.
- Channel and customer mix shifted toward increased Medicare and Medicaid revenue while exchanges saw membership declines that affected mix.
- Medical expense ratio rose notably as newly onboarded Performance Suite lives matured and claims costs increased, pressuring margins.
- SG&A declined through headcount reductions and changes to benefits and bonuses, even as the company continued investments in internal software and clinical programs.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.